CLDN18.2-positive gastric cancer: understand the result and next questions

Claudin 18.2 (CLDN18.2) is a protein that can be expressed by gastric and gastroesophageal junction adenocarcinoma. A pathologist evaluates tumour tissue by immunohistochemistry; a result must be read with the assay, staining threshold and clinical context.

A positive result is not the same as a treatment decision. Different medicines and studies can use different eligibility rules, so ask the hospital to review the original pathology report and the proposed therapy’s criteria.

First-line and later-line treatment questions are different. In the US, zolbetuximab plus specified chemotherapy is approved for first-line treatment of CLDN18.2-positive, HER2-negative unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, using an approved test. This US approval does not establish availability in China.

China’s announced satri-cel indication concerns CLDN18.2-positive, HER2-negative unresectable advanced gastric or gastroesophageal junction adenocarcinoma after progression following at least two prior lines. Other biomarkers, current condition and previous care can change the options.

• Pathology diagnosis and original CLDN18.2 report, including assay, staining and sample date if stated.
• HER2 and other available biomarker reports; tissue block or slide availability if known.
• Staging and recent scan reports with images where possible.
• Dated treatment history, current medicines and a current clinician summary.

Share existing reports first. A receiving team can say whether it needs pathology re-review, a new sample or another test. Do not assume a single positive line on a report is enough to plan a particular medicine or a trip.

Ask the specialist to state which treatment choice is being evaluated, whether it is locally approved or available, and how it compares with care near home.

A multidisciplinary review can confirm pathology, stage and biomarker interpretation, then consider the patient’s treatment line and overall condition. The proposed therapy may be a standard systemic regimen, a specific approved cellular therapy, a trial where appropriate, or supportive care.

A later-line CAR-T evaluation is a separate pathway from first-line antibody plus chemotherapy. Each has its own eligibility, logistics, safety monitoring and cost questions.

Ask for separate estimates for pathology review or repeat testing, consultations, the proposed treatment and monitoring, complication care and follow-up. Add travel, accommodation and interpretation after the likely pathway is clearer.

A sample can be insufficient or may need a different assay; biomarker expression and treatment requirements need specialist interpretation. Each potential therapy has its own side effects and evidence base. A reported trial benefit is not an individual outcome forecast.

The treating oncologist can review systemic therapy, other biomarker-led choices, clinical trials and symptom-focused care in light of HER2 and other results, prior therapy and patient goals. A China review should complement this discussion.

We can organise the reports, identify missing practical information and coordinate a focused hospital enquiry. The hospital makes testing and treatment decisions; no positive biomarker result guarantees access or benefit.